We examined the efficacy and host response to the adenovirus (Ad)-mediated delivery of human apolipoprotein A-I (APOA1) gene to the liver of APOA1 À/À mice. Administration of a first-generation vector (FGAd-AI) resulted in a transient appearance of APOA1 in plasma and induced an anti-APOA1 antibody titer, whereas treatment with a helperdependent vector (HDAd-AI) resulted in sustained APOA1 expression without inducing an antibody titer. With these results, we studied the effects of FGAd vectors on APOAI expression by HDAd-AI vector. Co-treatment with an FGAd vector inhibited HDAd-AI-mediated APOA1 expression independent of transgene cassettes, but only FGAd-AI induced a humoral response. Furthermore, APOA1 mRNA levels in mice co-treated with FGAd vectors were much lower than those expected from the vector copy number, suggesting that DNA of FGAd vectors interferes with the HDAd-AI vector's APOA1 promoter. A single treatment with an HDAd-AI vector produced a supraphysiological plasma APOA1 level that gradually declined to about half the normal human level over the course of 2 years, associated with a plasma cholesterol level that is persistently higher than that in controls. This investigation provides the proof of principle that liver-directed HDAd gene delivery is effective for the long-term phenotypic correction of monogenic hypoalphalipoproteinemia.
Introduction
High-density lipoprotein (HDL) deficiency constitutes the most common lipid abnormality in patients with coronary artery disease. 1, 2 Each mg/dl increase in circulating HDL cholesterol levels is associated with a 3% reduction in cardiovascular risk. 3 Apolipoprotien A-I (APOA1) is the main protein component of HDL and, epidemiological studies suggest that it may be a better marker of cardiovascular protection than HDL cholesterol itself. 4 In patients with a congenital deficiency of APOA1, a major cause of familial hypoalphalipoproteinemia, the marked deficiency of plasma HDL predisposes these patients to premature atherosclerosis. 5, 6 Population studies suggest that congenital APOA1 deficiency is not a rare condition. 7 If effective, long-term APOA1 gene therapy would be a definitive treatment of familial hypoalphalipoproteinemia caused by a congenital APOA1 deficiency. Furthermore, it would also be a method for reversing hypoalphalipoproteinemia or low HDL commonly associated with cardiovascular disease and should significantly reduce the risk of atherosclerotic cardiovascular disease in these patients.
Adenoviral vectors (Ads) efficiently transduce a variety of cell types including hepatocytes independent of cellular proliferation. Helper-dependent Ads (HDAds) are devoid of all viral protein genes; they display greatly attenuated toxicity and prolonged transgene expression following liver transduction in vivo. [8] [9] [10] [11] [12] [13] [14] In this investigation, we examined the effect of Ad-mediated gene transfer of the human APOA1 gene to the liver of APOA1 À/À mice, a mouse model for human familial hypoalphalipoproteinemia, to reverse the low HDL levels. We compared the efficacy of HDAd and firstgeneration Ad (FGAd-AI)-expressing human APOA1 gene to reverse the phenotype of mice with a congenital HDL deficiency. Induced APOA1 expressed in this model is a neoantigen and is predicted to elicit adaptive immunity. Interestingly, a significant anti-APOA1 antibody titer was found in mice treated with FGAd-AI but not with HDAd-AI. The appearance of an anti-APOA1 antibody titer was correlated with a fall in plasma APOA1 and cholesterol levels. To further understand the mechanisms by which FGAd-AI but not HDAd-AI induced an anti-APOA1 antibody titer, we studied the effect of co-injecting FGAd or HDAd with HDAd-AI. Coinjection of FGAd-AI inhibited HDAd-mediated APOA1 expression by inducing an anti-APOA1 antibody titer; it also led to a reduced HDAd-AI copy number in the liver. The fall in plasma APOA1 and decrease in hepatic HDAd-AI copy number were related to the co-injection of FGAd per se and not related to the transgene in these vectors. Finally, we monitored the effect of a single injection of HDAd-AI on phenotypic correction of APOA1 À/À mice and found persistent, near-normal plasma levels of human APOA1 and HDL at the end of 2 years.
Results

Production and characterization of HDAd vector
Taking advantage of the high capacity of HDAd vectors, we cloned an 11-kb human genomic APOA1 DNA into an HDAd (Figure 1a ). The vector was stable during amplification and exhibited no DNA rearrangement (Figure 1b) . It was free of helper virus contamination by Southern blot analysis ( Figure 1c ) and by real-time polymerase chain reaction (PCR), which has a detection limit of 0.001%.
Effects of adenoviral vector treatment on plasma cholesterol
To achieve phenotypic correction of an APOA1 deficiency in mice, we must express the APOA1 transgene at a high level to produce a normal APOA1 plasma concentration (100-150 mg/dl). 1 Our experience in two other mouse models of dyslipidemias 10, 11 suggests that a dose in the range of 0.5-4.5 Â 10 12 vector particles (VP)/ kg may be required to reverse the phenotype. 10, 11, 15 We, therefore, treated APOA1 À/À mice with escalating doses of HDAd-AI, starting at 5 Â 10 11 VP/kg (HDAd-AI-L),
increasing by a half-log increment to 1.5 Â 10 12 VP/kg (HDAd-AI-M) and finally using a maximum dose of 4.5 Â 10 12 VP/kg (HDAd-AI-H). An additional group of mice was treated with FGAd-AI (4.5 Â 10 12 VP/kg). Plasma APOA1 was barely detectable in mice treated with the lowest dose (n ¼ 4) (Figure 2a) . In HDAd-AI-M group, APOA1 was not detectable at day 3 and appeared in the plasma at a readily detectable level of 29733 mg/ dl (mean7s.d., n ¼ 5) at day 7. It gradually increased to a level similar to normal human subjects (100-150 mg/dl) 14 days after treatment (120775 mg/dl), reaching a plateau of 141754 mg/dl at day 28 and remained at this level for 70 days. In mice treated with the highest dose (HDAd-AI-H group), the plasma APOA1 level was not detectable at day 3 but increased to 867109 mg/dl 7 days after treatment and reached the highest level of 212743 mg/dl at day 28. In contrast, mice treated with FGAd-AI displayed a markedly elevated plasma APOA1 level (2267105 mg/dl) at day 3 and a peak level of 2977157 mg/dl at day 7. However, the supraphysiological plasma hAPOAI response following FGAd-AI administration was short-lived, as the protein was no longer detectable in plasma at day 28 ( Figure 2a and b) .
Appearance of APOA1 in plasma after gene transfer was associated with an increase in plasma cholesterol (Figure 2c ). FGAd-AI injection led to marked hypercholesterolemia that was out of proportion to the rise in plasma APOA1; it went up from a baseline of 2978 to 192791 mg/dl at day 3 and 365766 mg/dl at day 7, which may reflect hypercholesterolemia secondary to FGAd-associated liver damage. 16 The level rapidly declined on day 14 and was not significantly different from phosphate-buffered saline (PBS)-treated mice on day 28. In contrast, HDAd-AI-M and HDAd-AI-H groups did not show any change in plasma cholesterol Long-term phenotypic correction by a helper-dependent adenovirus K Oka et al until day 7, when it started to rise to a plateau at day 28. Mice treated with the lowest dose (HDAd-AI-L group) did not show any significant change in plasma cholesterol following treatment. At day 84, we fractionated plasma collected from HDAd-AI-H or PBS-treated mice by FPLC. By this analysis, we failed to detect any HDL in PBS-treated APOA1 -/-mice. HDAd-AI treatment led to the appearance of a prominent HDL cholesterol peak, the basis of the post-treatment total plasma cholesterol elevation (Figure 2d ).
Toxicity after treatment with FGAd-AI or HDAd-AI
We evaluated indices of hepatotoxicity in FGAd-AIand HDAd-AI-treated APOA1 À/À mice. Plasma alanine aminotransferase (ALT) activity increased significantly in FGAd-AI-treated mice at days 7 and 14 (101716 and 112715 IU/l, Po0.001 vs pretreatment levels of 127 8 IU/l, n ¼ 5), decreasing to 37716 IU/l at day 28 (Po0.05 vs pretreatment). In contrast, there was no significant change in ALT activity in the PBS-or HDAd-AI-treated groups (Figure 3a) . The increase in liver enzyme activity was correlated with abnormal liver histopathology ( Figure 3b and Table 1 ). Liver sections of FGAd-AI-treated mice at 8 days post-injection, displayed severe diffuse necrosis, increased inflammation, mitoses, hepatocellular nuclear pleomorphism and atypia. Signs of liver injury remained evident 80 days after treatment.
In contrast, HDAd-AI-treated mice as well as PBS controls showed minimal architectural disturbances and necroinflammation.
Previous studies in mice and baboons using FGAd and clinical experience with the E1-E4-deleted Ad vector suggest that thrombocytopenia is a sensitive indicator of early toxicity. [17] [18] [19] [20] We performed complete whole blood counts in mice treated with Ad vectors. Platelet counts dropped markedly in mice treated with 4.5 Â 10 12 VP/kg of FGAd-AI (90%, Po0.001 vs pretreatment, n ¼ 5) or 4.5 Â 10 12 VP/kg of HDAd-AI (77%, Po0.001, n ¼ 5) 3 days after injection. They were also significantly reduced, but to a much lesser extent, in mice treated with an intermediate dose of HDAd-AI (35%, Po0.001, n ¼ 4). Mice treated with either PBS or the lowest dose of HDAd-AI did not show a significant change in platelet counts (Figure 3c ). Platelet counts returned to pretreatment levels by day 7 in all groups. Thus, the effects of Ad vector treatment on platelets were dose dependent and occurred with both FGAd and HDAd. We detected no significant change in other blood parameters (e.g., WBC, RBC, MCV) among groups (data not shown).
FGAd-AI, not HDAd-AI, induces the appearance of anti-APOA1 antibodies
Newly synthesized APOA1 is a neoantigen and would be predicted to induce an antibody response in Abbreviations: APOA1, apolipoprotein A-I; FGAd-AI, first-generation vector; HDAd-AI, helper-dependent vector; PBS, phosphate-buffered saline; PMNs, peripheral mononuclear cells; VP, vector particle. APOA1 À/À mice were treated with 4.5 Â 10 12 VP/kg of HDAd-AI, FGAd-AI or PBS. The histopathological analysis was performed by a pathologist (MF) who was blinded to the type of treatment that the mice had received.
Long-term phenotypic correction by a helper-dependent adenovirus K Oka et al (Po0.05 vs pretreatment, n ¼ 5) and remained markedly elevated (1:500074900 dilution, Po0.05 vs pretreatment) at day 70. In contrast, the plasma anti-APOA1 antibody titer was not significantly changed by HDAd-AI treatment ( Figure 4b ).
Co-injection of FGAd suppresses HDAd-mediated APOA1 expression
FGAd vector not only induces T-cell-mediated immunity 21 but also adaptive immunity by its adjuvant effect through induction of cytokine release. 22, 23 In order to test whether FGAd induces a humoral immune response through its adjuvant effect and inhibits HDAd-AImediated APOA1 expression, we treated APOA1 À/À mice with both HDAd-AI and FGAd vectors and measured the antibody titer. We used human APOE3 gene as an unrelated gene that should not affect the anti-APOA1 antibody titer if the FGAd vector itself has no immunoadjuvant effects; furthermore, APOE3 expression can be differentiated from endogenous mouse APOE by a human-specific antibody. The total number of VP injected into mice was adjusted with HDAd-0 (empty vector). The vector structures are summarized in Table 2 . Co-injection of 5 Â 10 11 VP/kg of HDAd-AI and 5 Â 10 11 VP/kg of HDAd-E3 had no effects on plasma APOA1 levels and cholesterol levels compared with mice treated with HDAd-AI and HDAd-0, whereas co-injection of FGAd-AI or FGAd-E3 with HDAd-AI markedly attenuated the plasma APOA1 (and cholesterol) response. In mice treated with HDAd-AI and FGAd-E3, plasma APOA1 was undetectable throughout the course of the experiment (Figure 5a and b) . The lack of an APOA1 response in mice treated with either HDAd-AI and FGAd-AI or HDAd-AI and FGAd-E3 was confirmed by immunoblot analysis (Figure 5c , lanes 5 and 8 vs lane 6) whereas similar levels of APOA1 were detected in mice treated with HDAd-AI and HDAd-0 or HDAd-AI and HDAd-E3 (Figure 5c, lanes 6 and 7) . These data indicate that treatment with FGAd per se, regardless of its specific transgene insert or expression, suppresses HDAd-mediated APOA1 expression. However, we detected significant anti-APOA1 antibody titers only in mice treated with HDAd-0 and FGAd-AI or HDAd-AI and FGAd-AI. Interestingly, mice treated with HDAd-AI and FGAd-E3 did not develop anti-APOA1 antibodies (Figure 5d ), an observation that excludes the possibility of an FGAd adjuvant effect per se as a cause of inhibition of APOA1 expression.
To obtain a correlation between plasma APOA1 and immunoreactive APOA1 in the liver, we performed APOA1 immunofluorescence in liver sections of mice at day 56. The immunoreactivity was not detected in the (Figure 6h ). The low levels of APOA1 mRNA may be due to low vector copy number. We measured HDAd-AI vector copy number in the liver at day 1 (baseline) and day 56 after treatment by real-time PCR. The copy number fell significantly on day 56 in all groups, but much more so in the FGAd vector co-treated groups ( Figure 6i , lanes 2 and 4) than in HDAd vector co-treated groups (Figure 6i, lanes 1 and 3) . As APOE has been reported to display immunomodulatory properties, 24, 25 we treated mice with an FGAdexpressing mouse very-low-density lipoprotein receptor (VLDLR). VLDLR is normally expressed in APOA1 À/À mice and its induced overexpression does not induce a humoral immune response. 10, 26 The pattern of plasma cholesterol and APOA1 levels in mice treated with HDAd-AI and FGAd-VLDLR was similar to that in mice treated with HDAd-AI and FGAd-E3. An anti-APOA1 antibody was not detected in mice treated with HDAd-AI and FGAd-VLDLR, and the HDAd-AI vector copy number was 2.872.1 copies/diploid genome (n ¼ 5) at day 56. Therefore, the suppression of APOA1 expression by FGAd was independent of the transgene expressed.
Long-term phenotypic correction by a single injection of HDAd-AI As a moderate dose of HDAd-AI produces high plasma APOA1 levels without inducing anti-APOA1 antibodies, we tested the durability of the plasma APOA1 response in APOA1 -/-mice. We injected to these mice either PBS or 4.5 Â 10 12 VP/kg of HDAd-AI and monitored phenotypic correction over a 2-year period. Cholesterol levels in APOA1 À/À mice were 1074 mg/dl (mean7s.d., n ¼ 12) at baseline, compared with 64712 mg/dl (n ¼ 25) in 
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wild-type C57BL/6 mice. In PBS-injected mice, there was a spontaneous but slow increase in plasma cholesterol level over time to 3672 mg/dl at the end of 2 years (day 730), a phenotypic adjustment noted previously. 27 In the APOA1 À/À mice treated with HDAd-AI, cholesterol levels reached a maximal level of 104710 mg/dl (n ¼ 6) 4 weeks after injection and slowly declined over the next one and a half years to 5375 mg/dl. At 730 days, plasma cholesterol levels remained higher in all but one HDAd-AI-treated mice (58, 49, 27 and 76 mg/dl) than in controls (34 and 37 mg/dl), although the difference was not significant due to the small number of surviving control mice (Figure 7a) . We determined the plasma APOA1 level at day 366 and found it to be undetectable in PBStreated mice, but 140755 mg/dl (n ¼ 5) in HDAd-AItreated APOA1 -/-mice (normal human APOA1 ¼ 100-150 mg/dl). 1 At 730 days, three of the four surviving HDAd-AI-treated mice had values averaging 617 14 mg/dl. Thus, a moderate dose of HDAd-AI treatment led to high physiological levels of plasma APOA1 that declined to about 50% of the normal level at the end of 2 years (Figure 7b) . FPLC analysis revealed a prominent HDL cholesterol peak in plasma collected from HDAd-AI-treated mice at 366 and 540 days post-injection. It decreased to about half that of the wild-type mice at 730 days, but was still significantly higher than that in PBSinjected controls (Figure 7c-e) . By immunofluorescence, APOA1 immunoreactivity was detected in 30-40% of the hepatocytes in HDAd-AI-treated mice but was undetectable in PBS-treated controls (Figure 8d vs c) .
Discussion
A variety of problems associated with early generation Ad vectors has made them less than ideal vectors for liver-directed gene therapy. In contrast, HDAds have a significantly better safety profile and duration of transgene expression. [8] [9] [10] [11] [12] [13] [14] In this study, we compared the acute and chronic toxicities of HDAd and FGAd. Chronic hepatotoxicity caused by leaky Ad viral gene expression manifested by abnormal histopathology occurs with an FGAd, but is eliminated in a HDAd (Figure 3 , Table 1 ). However, acute toxicity is not significantly different between HDAds and FGAds. For example, dose-related thrombocytopenia occurs with both FGAds and 
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HDAds. 20, 28 The mechanism of Ad-induced thrombocytopenia appears to be multifaceted and complex. FGAd has been reported to increase platelet clearance. 29 Platelets express a V b 3 and other integrins that bind to the RGD motif, which is present in the penton base of Ad capsid proteins. However, incubation of platelet-rich human plasma with Ads fails to promote platelet aggregation, and the addition of an Ad vector had no effect on agonist-induced aggregation in vitro. 30 Finally, intravenous injection of lethal doses of FGAd in nonhuman primates causes diffuse endothelial damage that may lead to platelet activation, aggregation and depletion. 19, 31 There is a nonlinear dose-response to Ad vector transgene expression. [32] [33] [34] [35] Sequestration of an Ad vector by Kupffer cells may underlie this threshold effect. 35 Following systemic administration, Ads are taken up by macrophages, Kupffer cells, before they are taken up by hepatocytes. 33, 35 An acute cytokine response to systemic Ad vector administration in mice has been reported to be mediated by dendritic cells (DCs) and macrophages. 36 Thus, depletion of DCs or macrophages before therapeutic Ad administration is one strategy to reduce vector-associated acute toxicity as well as to increase hepatic transduction efficiency. 37 The enhancement of hepatocyte transduction has also been reported after preadministration of an unrelated Ad presumably to saturate the non-hepatic Ad-binding sites. 35 A previous study using an HDAd containing an APOE gene demonstrated a lifetime phenotypic correction of a genetic APOE deficiency in mice. 11 The current study aims to correct a heritable APOA1 deficiency, a much more common disorder, by APOA1 gene transfer. In these two apolipoprotein deficiency models, the newly synthesized transgene products are neoantigens. It is unclear how treated mice exhibit immuno-tolerance towards neoantigens, permitting unattenuated long-term transgene expression after HDAd-AI delivery. C57BL/6 mice have been reported to be more immuno-tolerant than other strains. 38, 39 However, FGAd-AI-treated C57BL/6 mice develop anti-APOA1 antibodies, indicating that they can mount a humoral immune response. One potential explanation for the transient nature of transgene expression of FGAd-AI and the FGAd-AImediated suppression of HDAd-AI vector-mediated APOA1 expression is an FGAd-mediated adjuvant effect via cytokine release. 22 Our experiment co-injecting HDAd-AI and FGAd-E3 rules out an adjuvant effect of FGAd per se as the explanation. Also refuting the possibility of an adjuvant effect by FGAds is the good level of APOE3 expression 56 days after FGAd-E3 treatment (Figure 5c ). 
HDAds have been shown to have an attenuated adaptive immune response compared with FGAds. 40 De Geest et al. 41 have reported the strict dependence of mouse humoral anti-APOA1 immune response on APOA1 expression in antigen-presenting cells. Although the experimental design of the current study differs from those of previous reports using wild-type C57/BL6 mice in which APOA1 is not a neoantigen, [41] [42] [43] our data support the notion that antigen presentation in APCs is required to induce a humoral response against APOA1. Our study also corroborates reports indicting that the use of a liver-specific promoter that avoids expression in antigen presenting cells reduces the immune response towards transgene products. 42, 44 Although co-injection of FGAd-E3 or FGAd-VLDLR with HDAd-AI failed to induce an anti-APOA1 antibody in APOA1 À/À mice, these FGAds decreased the HDAd vector copy number. Eleven to fifteen percent of vector DNA were present in these mice compared to control mice (Figure 6i ). Substantial transgene expression, despite accelerated loss of vector DNA, has been reported in HDAd-mediated dystrophin expression in mdx mice. 45 Therefore, undetectable APOA1 expression in the liver and in the plasma of mice treated with both HDAd-AI and an FGAd vector was unexpected in the absence of APOA1 neutralizing antibodies (Figure 6g ). In addition to reduced vector copy number, FGAd genome or CMV promoter used in these vectors may have further inhibited transcription of the human APOA1 gene. Bacterial DNA sequences have been suggested to play a role in episomal transgene silencing in a nonviral vector, which is mediated by a covalent linkage of the expression cassette and the bacterial DNA elements. 46, 47 Although promoter silencing of nonviral DNA was promoter/enhancer independent, we found that it was promoter-dependent in the current study. Substantial APOE3 expression driven by CMV promoter was evident in mice treated with HDAd-AI and FGAd-E3 56 days after treatment, whereas APOA1 expression was undetectable (Figure 5c, lane 8) . DNA of an FGAd vector may function as an insulator or a low-level leaky expression of FGAd gene may interfere with the transcription of episomal transgene driven by a mammalian promoter. Alternatively, competition of a viral promoter with APOA1 promoter is in play. 48 Data supporting this notion have been reported by Wen et al. 49 who found enhanced but not suppressed HDAd vector-mediated urokinase plasminogen activator expression following FGAd co-administration in which the transgene delivered by HDAd vector was driven by CMV promoter.
Owing to the adverse events of integrating viral vectors, non-integrating viral vectors such as Ad vector have emerged as a preferred vector for some gene therapy applications. Although the frequency of chromosomal integration of an HDAd vector has been reported to be slightly higher than that of an FGAd, 50, 51 HDAds are essentially non-integrating vectors, and transgene expression is eventually eliminated with repeated cell divisions. Despite long-term phenotypic correction, the plasma APOA1 level declined from supraphysiological level at 4 weeks to 50% of normal level over 2 years. We previously showed that the same HDAd produced with helper viruses of different serotypes can re-stimulate transgene expression. By alternating serotypes, a therapeutic level of transgene expression can be maintained for an extended time period. 
Materials and methods
Recombinant adenoviral vectors
The HDAd-AI contains the 11-kb EcoR1 fragment of the human APOA1 gene, including the 5.5 kb of 5 0 and 3.5 kb of 3 0 flanking DNA on a pD21 backbone. 11 Rescue and amplification of the HDAd-AI were performed by the method of Parks et al. 52 The absence of DNA rearrangement and helper virus contamination were analyzed by Southern blot. Human APOA1 cDNA was cloned into a KS vector by reverse transcription-PCR using total cellular RNA prepared from HepG2 cells. The following primers were used: 5 0 -GAA GGA TCC ACC ATG AAA GCT GCG GTG CTG AC-3 0 and 5 0 -AAG GAA TTC ACT GGG TGT TGA GCT TCT-3 0 . They contained artificial cloning sites (underlined) and the Kozak sequence (bold faced) at the translation initiation codon. The nucleotide sequence was verified by DNA sequence analysis, and the APOA1 cDNA was subcloned into the pAvCvSv shuttle vector. 53 FGAd-AI was produced by standard techniques. Both vectors were produced on serotype 5. Human apoE3-expressing Ad vectors were produced using human APOE3 cDNA or an 11-kb HindIII fragment containing APOE3 gene and the liver enhancer element. 11 An FGAd-expressing mouse VLDLR has been described. 10 HDAd-0 (empty vector) was made on pC4HSU backbone. 54 The infectious titer of FGAd-AI was determined by a standard plaque assay, and that of HDAd-AI was determined by a DNA-based method as described by Kreppel et al. 55 The infectious unit/vector particle ratios of FGAd-AI and HDAd-AI were 1:20 and 1:17, respectively.
Animal studies
Female APOA1
À/À mice on a C57BL/6 background were purchased from Jackson Laboratories and were kept on a regular chow diet. Experiments were performed at 9-13 weeks of age with an average weight of 20 g. To conduct the dose-response study, mice (4-5 per group) were injected via tail vein with PBS; HDAd-AI at escalating doses: 5 Â 10 10 13 VP/kg) was adjusted with HDAd-0 (empty vector). Long-term transgene expression was evaluated for up to 2 years after the virus treatment at the dose of 4.5 Â 10 12 VP/kg. A control group received PBS. For plasma determinations, mice were fasted for 5 h, anesthetized with methoxyfluorane or isofluorane, and blood was collected in ethylene diaminetetraacetic acid by puncturing the saphenous vein or the retro-orbital plexus. 10, 11 Phenotype analysis Cholesterol and FPLC analyses were performed as previously described. 10 Plasma human APOA1 levels were quantified by an immunoturbidometric assay adapted for a 96-well plate format (Diasorin). HDL cholesterol was determined by FPLC. Two or three sets of pooled plasma (200 ml) from control and HDAd-AI-treated mice were used for these determinations. For human APOA1 immunoblot analysis, plasma was diluted 1:32, electrophoresed on a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to a nitrocellulose membrane. The membrane was then incubated with a goat anti-human APOA1 antibody (1:2000 dilution, Chemicon, Temecula, CA, USA) with detection using enhanced chemiluminescence (ECL) (Amersham Pharmacia Biotech, Piscataway, NJ, USA). For APOE3 immunoblot, goat anti-APOE antibody (1:4000, Calbiochem, La Jolla, CA, USA) or mouse monoclonal anti-human APOE3 (1:1000, SIGNET Lab, Dedham, MA, USA) were used.
Immunohistochemistry
Approximately 3 mm thick sections of the left-lateral lobe of the liver were embedded in OCT and stored at À801C. Cryosections (5 mm-thick) were fixed in cold acetone at À201C for 5 min, blocked with 1% bovine serum albumin (BSA) for 1 h, and used for immunofluorescence staining. The sections were incubated with a goat anti-human APOA1 antibody (1:100) in 1% BSA for 30 min at 371C washed with PBS (pH 7.2), and incubated with rabbit anti-goat antibody conjugated to Alexa Fluor 488 (1:200, Molecular Probes, Eugene, OR, USA). The slides were mounted with Vectashield Mounting Medium with 4,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA, USA), and the images were captured with the Axioplan 2 microscope and Axiovision 4.1 software (Carl Zeiss, Goettingen, Germany).
Toxicity studies
Histological analyses were performed on formalin-fixed, paraffin-embedded tissues as described previously. 18 ALT activity and whole blood counts were determined on fresh samples by the Clinical Pathology Laboratory in the Center for Comparative Medicine at Baylor College of Medicine (Houston, TX, USA).
Detection of anti-human APOA1 antibodies
For detection of an anti-APO1 antibody by immunoblot assay, 1.4 mg of purified human HDL were separated on a 4-20% SDS-PAGE, transferred to a nitrocellulose membrane, and incubated with plasma collected from mice treated with Ad vectors as a primary antibody (1:1000). The anti-human APOA1 antibody titer was also determined by direct ELISA. A flat bottom 96-well EIA/RIA medium binding plate (Costar, Corning, NY, USA) was coated with 50 ml of purified human HDL (Calbiochem, 200 ng/well) at 41C overnight. After washing the plate with 20 mM Tris-buffered saline pH 7.5 (TBS) containing 0.05% Tween 20 (TBS-T), the plate was blocked with TBS-T containing 4% skim milk, and incubated with plasma diluted with TBS-T. After washing, the plate was incubated with 50 ml of peroxidase-conjugated goat antimouse IgG (Pierce, Rockford, IL, USA, 1:1000 dilution with 0.1 Â blocking solution). The plate was washed and incubated with 100 ml of substrate (Pierce 1-Step Turbo TMB-ELISA) for 30 min at room temperature while being protected from light. The reaction was terminated by an addition of 100 ml of 1 M H 2 SO 4 solution, and the plate was read at 450 nm. The titer of antibodies was defined Long-term phenotypic correction by a helper-dependent adenovirus K Oka et al as the reciprocal of the highest dilution giving an optical density of 0.1 at 450 nm.
Northern blot and RT-PCR analyses
Total cellular RNA was prepared using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Twenty micrograms of RNA were electrophoresed on a 1.2% formaldehyde/ agarose gel, transferred to a nylon membrane, and hybridized to a 32 P-labeled 0.8 kb human APOA1 cDNA probe. For RT-PCR, the following primers were used: 5 0 -ATT GTT GCC ATC AAC GAC CC-3 0 and 5 0 -CCA CGA CAT ACT CAG CAC C-3 0 for mouse GAPDH mRNA; 5 0 -ACGTGGATGTGCTCAAAGACAG-3 0 and 5 0 -ATCCTTGCTCATCTCTTGCCTC-3 0 for human APOA1 mRNA.
Detection of adenoviral vector genomes in tissue samples
Ad vector DNA was obtained from the liver using DNA kit (Qiagen, Valencia, CA, USA) and the vector copy number was determined by quantitative real-time PCR of the vector backbones using SYBR Green QPCR master mix (Bio-Rad, Hercules, CA, USA). The PCR primers for pD21-based HDAd vectors were: 5 0 -TTGGGCGTAACC GAGTAAG-3 0 and 5 0 -ACTTCCTACCCATAAGCTCC-3 0 .
Statistics
Statistical analyses on lipid data were performed by two-way analysis of variance (ANOVA) with factors time and treatment group (HDAd-AI vs control) or by oneway ANOVA using SigmaStat (SYSTAT Software Co., Point Richmond, CA, USA). Statistical significance was assigned at Po0.05.
